Global Urinary Tract Cancer Market Size study & Forecast, by Cancer Type, Treatment Type, and Distribution Channel and Regional Analysis, 2022-2029

  • Publish Date: Nov,2022
  • Report ID: 3-2-1177
  • Page : 200
  • Report Type : PDF (Email)
Global Urinary Tract Cancer Market is valued approximately USD 2.02 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2022-2029. Urinary Tract Cancer is a type of cancer that affects urethra, bladder, and renal pelvic. Urethral cancer affects the tube that carries urine from bladder to outside of the body. Whereas in Bladder Cancer the healthy cells in the bladder lining called as urothelial cells, change, and grow out of control and form a tumor. Chemotherapy, and Immunotherapy are used as treatment procedure for treatment of Urinary Tract Cancer. The increasing prevalence of bladder cancer and growing number of funding activities from private & government organizations as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to the World Cancer Research Fund International - in 2020, around 573278 new cases of bladder cancer were reported worldwide, representing 3.2% of all cancer type. Moreover, as per American Cancer Society's estimates - in 2022, around 81,180 new cases of bladder cancer (about 61,700 in men and 19,480 in women) reported across the United States. In addition, around 17,100 individuals lost their lives due to bladder Cancer. Also, surge in sedentary lifestyle and rising healthcare infrastructure in emerging regions would create lucrative growth prospectus for the market over the forecast period. However, the high treatment cost associated with Urinary tract cancer and side effects associated with prescribed drugs impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Urinary Tract Cancer Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as Increasing incidences of bladder cancer as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising number of geriatric individuals as well as increasing penetration of super specialty hospitals and cancer care centers in the region.

Major market players included in this report are:

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Eli Lily and Company

Endo International plc.

Exelixis, Inc.

GlaxoSmithKline Plc. (GSK)

Merck KGAA

Novartis AG

Pfizer Inc.

Johnson & Johnson

Recent Developments in the Market:

In April 2019, Janssen Pharmaceutical received the US Food and Drug Administration (FDA) approval for the drug Balversa (erdafitinib). This new drug is intended for treatment of metastatic urothelial carcinoma (mUC), a type of bladder cancer.
In September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib, for the treatment of renal cancer. This new drug would be available in 20mg/40mg/60mg formulation.
Global Urinary Tract Cancer Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered Cancer Type, Treatment Type, Distribution Channel, Region

Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Cancer type

Bladder Cancer

Urethral cancer

Ureteric and Renal Pelvic Cancer

By Treatment Type



By Distribution Channel

Retail Pharmacy

Online Pharmacy

By Region:

North America










Asia Pacific





South Korea


Latin America



Rest of the World